Consistent with these findings, de-induction of HER2 expression in HER2+ mouse mammary tumors derived from MMTV-rtTA-TetO HER2 transgenic mice [9] resulted in a dramatic loss of CDK7 expression and decreased phosphorylation of RNA Pol II CTD (Fig. 3b). This evidence concerns the gene ERBB2 and breast cancer.